[Farnesyltransferase as target for non-cytotoxic anti-cancer agents: first steps].
Farnesylation is a key maturation step involved in the ras-dependent transformation of cells. This acylation step is catalyzed by protein: farnesyltransferase, a soluble enzyme. The present work describes the use of a new HPLC method of measurement of this enzymatic activity using the K-ras-derived CVIM tetrapeptide as substrate. The method is used to check the activity catalyzed by cytosols issued from various types of cancer cells. J82, a human bladder cancer cell line was retained for measurement of the inhibitory potency of a few peptide sequences and will be used as starting biological material for the purification of the enzyme. This HPLC method presented herein has the main advantages over other published methods of being automatisable and versatile, because it can be used with a wide spectrum of peptide substrates. Results presented herein are only first studies and need some more structural observations. The obtention of the cancer cell line-derived, partially purified farnesyltransferase will hopefully lead us to the discovery of specific inhibitors with potential non-cytotoxic anti-cancer activities.
Tassin
J P
JP
Institut de Recherches Servier, Division de Cancérologie expérimentale, Suresnes, France.
Boutin
J A
JA
Ernould
A P
AP
Atassi
G
G
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D002277:Carcinoma / Q000473:pathology; D004122:Dimethylallyltranstransferase / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D007938:Leukemia / Q000473:pathology; D007942:Leukemia, Experimental / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000201:enzymology; D001749:Urinary Bladder Neoplasms / Q000473:pathology
D000970:Antineoplastic Agents; D004122:Dimethylallyltranstransferase
La farnésyltransférase comme cible d'agents anti-cancéreux non cytotoxiques: premiers pas.